Precipio, inc. (PRPO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Service revenue, net

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical research grants

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue, net of contractual allowances and adjustments

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue, net of contractual allowances and adjustments

4,660

4,095

4,032

3,809

3,569

3,448

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

1,030

968

908

819

704

584

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

3,630

3,127

3,124

2,990

2,865

2,864

0

0

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET SALES

-

-

-

-

-

-

-

-

-

-

-

-

1,979

-

-

-

1,415

1,929

-14,317

-10,583

-4,261

1,240

23,297

25,879

26,421

27,544

28,618

29,861

31,648

31,480

32,759

33,123

31,697

31,971

27,819

24,661

0

0

0

Service revenue

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

3,324

2,908

2,849

2,754

2,626

2,639

2,332

2,018

1,660

1,431

1,875

1,759

1,716

1,762

1,542

1,756

1,980

1,940

-6,925

-5,023

-1,117

2,175

14,617

16,466

16,428

16,790

18,274

18,167

18,365

18,348

16,010

15,729

14,310

13,534

12,648

11,448

0

0

0

Gross profit

306

219

275

236

239

225

382

316

117

292

-235

-24

263

-205

-30

-279

-565

-11

-7,392

-5,560

-3,144

-935

8,680

9,413

9,993

10,754

10,344

11,694

13,283

13,132

16,749

17,394

17,387

18,437

15,171

13,213

0

0

0

OPERATING EXPENSES:
Operating expenses

-

-

9,040

9,480

-

9,452

8,917

8,627

7,046

6,488

0

0

6,108

-

0

-

6,955

7,055

-3,131

246

3,901

7,385

20,696

22,859

22,278

23,301

22,833

21,166

21,462

20,145

20,705

19,510

19,821

19,150

16,435

15,104

0

0

0

Impairment of goodwill

-

-

-

-

-

-

0

0

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

1,286

-

-

-

1,672

1,853

1,452

1,638

1,955

2,249

3,076

3,065

3,193

3,212

2,927

2,965

2,706

2,491

2,438

2,285

2,210

2,218

2,264

2,261

0

0

0

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

41

112

107

0

0

0

Operating expenses

11,444

11,213

12,156

13,871

13,762

14,137

18,652

18,102

16,521

15,803

10,682

7,623

7,394

7,614

5,155

6,799

8,627

8,908

-1,679

1,884

5,856

9,634

23,772

25,924

25,471

26,513

25,760

24,131

24,168

22,636

23,144

21,801

22,048

21,409

18,811

17,472

0

0

0

OPERATING LOSS

-11,138

-10,994

-11,881

-13,635

-13,523

-13,912

-18,270

-17,786

-16,404

-15,511

-10,917

-7,647

-7,131

-7,819

-5,185

-7,078

-9,192

-8,919

-5,713

-7,444

-9,000

-10,569

-15,092

-16,511

-15,478

-15,759

-15,416

-12,437

-10,885

-9,504

-6,395

-4,407

-4,661

-2,972

-3,640

-4,259

0

0

0

OTHER INCOME (EXPENSE):
Interest expense, net

-1,163

-473

-391

-414

-284

-269

-150

-1,913

-2,085

-2,324

-2,923

-1,176

-1,116

-1,038

-639

-677

-703

-724

-725

-713

-673

-665

-673

-666

-671

-642

-636

-688

-768

-888

-953

-984

-993

-958

-716

-477

0

0

0

Warrant revaluation

1,112

416

1,139

752

1,897

1,918

537

394

68

-226

463

430

434

788

147

532

261

-205

-80

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on modification of warrants

-

-

-

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative revaluation

-

-415

-298

-299

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on settlement of liability, net

-

1,437

1,301

1,367

289

263

0

0

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) gain on extinguishment of debt

-

-

-

-

-

-

0

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of convertible notes

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on litigation

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of convertible notes

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on settlement of equity instruments

-

-

-

-

-

-385

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Merger advisory fees

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant revaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

450

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of product line

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Expense on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,066

6,866

6,266

0

0

0

Warrant revaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-1,000

-1,000

0

-

0

0

-

-

-

Total other nonoperating income (expense)

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

0

-18

-13

-13

0

5

7

7

60

43

36

44

11

51

55

48

259

230

232

0

0

0

Total other expenses

-3,728

-2,319

-4,435

-4,633

-1,663

-2,061

0

0

0

-

-

-

-882

-450

-487

-146

-443

-943

-518

-936

-426

-210

-768

-709

-714

-282

1,207

1,148

1,876

1,323

898

271

-4,984

-6,765

-7,352

-6,511

0

0

0

LOSS BEFORE INCOME TAXES

-14,866

-13,313

-16,316

-18,268

-15,186

-15,973

-18,018

-20,449

-21,298

-20,694

-17,030

-11,249

-8,013

-8,269

-5,672

-7,224

-9,635

-9,862

-6,231

-8,380

-9,426

-10,779

-15,860

-17,220

-16,192

-16,041

-14,209

-11,289

-9,009

-8,181

-5,497

-4,136

-9,645

-9,737

-10,992

-10,770

0

0

0

INCOME TAX BENEFIT

-

-

-

-

-

-

-

-

-

349

0

0

0

0

1

1

0

0

958

-498

-505

0

-1,065

383

385

-54

110

232

208

146

252

129

55

45

-48

50

0

0

0

LOSS FROM CONTINUING OPERATIONS

-

-

-

-

-

-

-

-

-

-

-

-

-8,013

-

-

-

-9,635

-9,862

-9,967

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

INCOME (LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAXES

-

-

-

-

-

-

-

-

-

-

-

-

1,899

-

-

-

-23,542

-23,092

-3,728

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET LOSS

-14,796

-13,243

-16,037

-17,989

-14,907

-15,694

-18,091

-20,522

-21,371

-20,694

-15,131

-9,350

-6,114

-7,616

-23,546

-30,346

-33,177

-32,954

-19,408

-12,189

-12,807

-13,942

-12,131

-17,603

-16,577

-15,987

-14,319

-11,521

-9,217

-8,327

-5,749

-4,265

-9,700

-9,782

-10,944

-10,820

0

0

0

Deemed dividends related to beneficial conversion feature of preferred stock and fair value of warrant down round features

0

-

-

-

-

4,222

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred dividends

-

-

-

-

-

-

-

-

-

-

0

-

0

393

724

1,055

1,386

1,324

1,297

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

TOTAL DIVIDENDS

0

-

-

-

-

4,222

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

899

775

726

708

692

676

660

703

813

915

1,010

802

527

0

0

0

NET LOSS AVAILABLE TO COMMON STOCKHOLDERS

-18,140

-13,243

-16,411

-18,363

-15,615

-19,916

-25,358

-31,637

-37,400

-33,209

-24,227

-14,598

-6,114

-8,009

-24,270

-31,401

-34,563

-34,278

-20,706

-13,460

-14,052

-15,086

-13,153

-18,502

-17,352

-16,713

-15,027

-12,213

-9,893

-8,987

-6,452

-5,078

-10,615

-10,792

-11,746

-11,347

0

0

0

BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)

-0.78

-0.49

-0.31

-1.05

-0.48

-1.94

-2.49

-2.29

-7.10

9.62

-1.36

-15.35

-0.07

2.01

-1.15

-1.03

-0.18

-1.57

-0.55

-0.30

-0.36

-0.79

-0.05

-0.57

-0.60

-0.57

-0.78

-0.41

-0.54

-1.45

-0.04

-0.01

-0.05

-2.40

-0.03

-0.13

-0.06

-0.02

-0.02

BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

8,371

7,497

6,186

5,655

3,441

1,996

1,546

1,382

838

-16,235

7,430

581

26,779

69,571

435

429

20,323

13,981

13,763

12,149

9,392

7,914

7,353

7,353

7,353

7,358

7,353

7,353

7,000

-182,795

71,645

71,645

62,683

-

-

-

-

-

-

BASIC AND DILUTED WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49,327

49,299

49,293

49,289

49,206

Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments

4,599

4,051

3,962

3,750

3,454

3,335

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

less allowance for doubtful accounts

1,030

968

896

776

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

3,569

3,083

3,037

3,036

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

-

-

2,824

2,721

-

2,549

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical research grants [Member]
Revenue, net of contractual allowances and adjustments

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total cost of sales

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other [Member]
Revenue, net of contractual allowances and adjustments

61

44

45

21

15

13

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-